Lumax Auto Technologies Q3 Performance: Profit Soars 83% YoY, Margins Expand

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Lumax Auto Technologies Q3 Profit Soars 83%, Revenue Jumps 40%

With the third quarter earnings season drawing to a close, there will be a beeline of companies reporting their quarterly results in the upcoming week. A combination of Nifty 50 companies, F&O stocks, and new listings as well, will be part of the list for the week. Here's a look at some of the major earnings that you should have your eyes on:

C

CNBC TV18•12-02-2026, 15:44

Lumax Auto Technologies Q3 Profit Soars 83%, Revenue Jumps 40%

•Lumax Auto Technologies reported a net profit increase of 83.3% to ₹82.5 crore in Q3.
•Revenue from operations climbed 40.3% to ₹1,270.6 crore year-on-year.
•EBITDA rose 49.2% to ₹176 crore, with margins expanding to 13.8%.
•Shares closed up 1.54% at ₹1,754 on NSE after the earnings announcement.
•Company approved a First Loss Deficiency Guarantee for channel partners with ICICI Bank to facilitate financing.

Read Full Article on Cnbc in English

✦

More like this

✦

More like this

Lumax Industries का स्टॉक 20% बढ़कर 6,136.30 रुपये पर बंद हुआ।

Lumax Industries Shares Soar 20% on Robust Q3 Earnings, Hits 52-Week High

Lumax Auto Tech | Among the nine names highlighted by SBI Securities, Lumax Auto Tech has the highest potential upside. The brokerage has a price target of ₹854 on the stock, which implies a potential upside of 51% from current levels.

Lumax Shares Soar 20% to 52-Week High on Robust Q3 Earnings

Lupin said the US drug regulator has classified its inspection of the Pithampur Unit 2 manufacturing facility as 'official action indicated' (OAI).

The US Food and Drug Administration (USFDA) had conducted inspections at the facility from July 8 to July 17, 2025, and closed it by issuing Form 483 with four observations.

Lupin Q3 Net Profit Jumps 38% on Strong US Sales, Divestment Gains

Lupin said the US drug regulator has classified its inspection of the Pithampur Unit 2 manufacturing facility as 'official action indicated' (OAI).

The US Food and Drug Administration (USFDA) had conducted inspections at the facility from July 8 to July 17, 2025, and closed it by issuing Form 483 with four observations.

Lupin's Ankleshwar Facility Gets 2 US FDA Observations; Q3 Profit Up 37.5%

accumulate

Prabhudas Lilladher Recommends 'Accumulate' on Lupin, Sets Rs 2400 Target

Lupin Raises FY26 Margin Guidance to 27-28% Amid Strong Growth

Lupin Raises FY26 Margin Guidance to 27-28% Amid Strong Growth